Relay Therapeutics Inc

+0.56 (+3.52%)
5:34:38 PM EDT: $16.80 +0.33 (+2.00%)
Products, Strategic Combinations

Relay Therapeutics Announces Worldwide License Agreement And Collaboration With Genentech

Published: 12/14/2020 11:45 GMT
Relay Therapeutics Inc (RLAY) - Relay Therapeutics Announces a Worldwide License and Collaboration Agreement With Genentech for Rly-1971.
Relay Therapeutics Inc - Will Receive $75 Million Upfront and is Eligible to Receive an Additional $25 Million in Near-term Payments.
Relay Therapeutics Inc - Will Receive $695 Million in Additional Potential Milestones, Plus Royalties on Global Net Product Sales.
Relay Therapeutics Inc - Genentech Will Assume Development of Rly-1971 With Potential to Expand Into Multiple Combination Studies.
Relay Therapeutics Inc - Also Has Right to Opt in to a 50/50 U.S. Profit/cost Share on Rly-1971.
Relay Therapeutics Inc - Retains Right to Combine Rly-1971 With Its Selective Fgfr2 and Mutant-selective Pi3kΑ Programs.
Relay Therapeutics Inc - With Execution of Collaboration, Co Anticipates It Will Have Cash and Investments to Sustain Operations Through 2024.